Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors
Jesus M. Ontoria(IRBM Science Park), Philip Jones(The University of Texas MD Anderson Cancer Center), Caterina Torrisi(IRBM Science Park), Claudia Giomini(IRBM Science Park), Michael Rowley(IRBM Science Park), Laura Llauger Bufi(IRBM Science Park), Alberto Bresciani(University of Bergamo), Christian Steinkühler, Sergio Serafini(IRBM Science Park), Bin Hu(WuXi AppTec (China)), Hao Wu(Hefei University of Technology)
Cited by 28
Related Papers
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
|Nature Medicine|2023|372
Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors
|Nature Medicine|2006|339
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
|Cancer Research|2015|275
Cancer Stem Cell‐Platelet Hybrid Membrane‐Coated Magnetic Nanoparticles for Enhanced Photothermal Therapy of Head and Neck Squamous Cell Carcinoma
|Advanced Functional Materials|2019|208
Adipogenesis of skeletal muscle fibro/adipogenic progenitors is affected by the WNT5a/GSK3/β-catenin axis
|Cell Death and Differentiation|2020|149